Back to results
US 11,642,377 B2Granted
Bone marrow derived neurokinin-1 receptor positive (NK1R+) mesenchymal stem cells for therapeutic applications
AssigneeBioCardia, Inc.
InventorsIan McNiece, Peter Altman
Life of this patent
Estimating the term…
Abstract
The present disclosure provides use of neurokinin 1 receptor (NK1R) as a marker for identifying and/or isolating multipotential cells. The present disclosure provides cell populations enriched by methods of the present disclosure and therapeutic uses of these cells and agents derived from these cells.
Claims16
A method of treating a disease or disorder comprising:
- isolating mesenchymal stem cells (MSCs) that express neurokinin-1 receptor (NK1R+ MSCs) from a bone marrow of a human subject by using an antibody to NK1R;
- and
- administering to a patient a therapeutically effective amount of the NK1R+ MSCs to treat the diseases or disorders, wherein the disease or disorder is selected from the set of:
- cardiovascular disease, pain, rheumatoid arthritis, diabetes, stroke, asthma, pulmonary fibrosis, and aging.
1 more element
A method of treating a disease or disorder comprising:
- isolating mesenchymal stem cells (MSCs) that express neurokinin-1 receptor (NK1R+ MSCs) from a bone marrow of a human subject by using an antibody to NK1R;
- culturing and expanding the NK1R+ MSCs ex vivo;
- and
- administering to a patient a therapeutically effective amount of the NK1R+ MSCs to treat the diseases or disorders, wherein the disease or disorder is selected from the set of:
- cardiovascular disease, pain, rheumatoid arthritis, diabetes, stroke, asthma, pulmonary fibrosis, and aging.
2 more elements
Dependencies are inferred from the claim text.